Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: ALNA®
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4575
- Registration Number
- NCT02244333
Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 493
- Registration Number
- NCT02244242
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13066
- Registration Number
- NCT02245464
Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7391
- Registration Number
- NCT02245503
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4150
- Registration Number
- NCT02244320
Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms
Phase 2
Completed
- Conditions
- Lower Urinary Tract Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 74
- Registration Number
- NCT02244281
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1060
- Registration Number
- NCT02245555
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Ascending doses of HYTRIN® capsules
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1993
- Registration Number
- NCT02244255
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Matching placebo capsule
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 153
- Registration Number
- NCT02245490
The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: ALNA®OCAS®
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5775
- Registration Number
- NCT02245542